Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.33 |
| ▸ | PRKDC | P78527 | 2/20 | 0.33 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31647268 | 0.98 | L3MBTL1 (0.47) | L3MBTL1DYRK1AKEAP1PDE4APDE3A | |
| SCHEMBL20406365 | 0.85 | L3MBTL1 (0.49) | L3MBTL1DYRK1AKEAP1PDE4APDE3A | |
| SCHEMBL11985799 | 0.82 | L3MBTL1 (0.44) | L3MBTL1DYRK1AKEAP1PDE4APDE3A | |
| SCHEMBL22745442 | 0.81 | L3MBTL1 (0.44) | L3MBTL1DYRK1AKEAP1PDE4APDE3A | |
| SCHEMBL25233154 | 0.77 | DYRK1A (0.41) | L3MBTL1DYRK1AKEAP1MEN1CYP1A2 | |
| SCHEMBL27452784 | 0.77 | L3MBTL1 (0.41) | L3MBTL1DYRK1AKEAP1PDE4APDE3A | |
| SCHEMBL3323254 | 0.77 | L3MBTL1 (0.41) | L3MBTL1DYRK1AKEAP1PDE4APDE3A | |
| SCHEMBL16581970 | 0.77 | L3MBTL1 (0.41) | L3MBTL1DYRK1AKEAP1PDE4APDE3A | |
| SCHEMBL24087352 | 0.77 | TGFBR1 (0.38) | L3MBTL1DYRK1AKEAP1MEN1CYP1A2 | |
| SCHEMBL338573 | 0.77 | PDE4A (0.41) | L3MBTL1DYRK1AKEAP1PDE4APDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3321268-B1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2025-06-04 | — | — | EP | disclosed |
| CN-112867715-B | 5-azaindazole derivatives as adenosine receptor antagonists | 默克专利股份公司 | 2024-03-05 | — | — | CN | disclosed |
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| EP-3870582-B1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2023-07-19 | — | — | EP | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20220289732-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | NOVARTIS AG (CH) | 2022-09-15 | — | — | US | disclosed |
| EP-2048142-A2 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2009-04-15 | — | — | EP | disclosed |
| EP-1382603-B1 | NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-7074801-B1 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | EISAI CO., LTD. (JP) | 2006-07-11 | — | — | US | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
| EP-0199127-B1 | 5-(6-imidazo[1,2-a]pyridyl) pyridine derivative | Eisai Co., Ltd. (JP) | 1989-12-13 | — | — | EP | disclosed |
| US-4803276-A | CARDIOTONIC AGENTS, VASODILATION | EISAI CO., LTD. (JP) | 1989-02-07 | — | — | US | disclosed |
| US-4791203-A | CARDIOTONIC AGENTS | EISAI CO., LTD. (JP) | 1988-12-13 | — | — | US | disclosed |
| US-4791202-A | CARDIOTONIC AGENTS; CONGESTIVE HEART FAILURE | EISAI CO., LTD. (JP) | 1988-12-13 | — | — | US | disclosed |
| US-4751227-A | 3-cyano-5-(6-imidazo[1,2-a]pyridyl)pyridin-2-ols useful as cardiotonics | EISAI CO., LTD. (JP) | 1988-06-14 | — | — | US | disclosed |
| EP-0199127-A1 | 5-(6-imidazo[1,2-a]pyridyl) pyridine derivative | Eisai Co., Ltd. (JP) | 1986-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | C3AR1, C9, C1R | L3MBTL1 629/4885DYRK1A 4426/4885KEAP1 82/4885 |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | L3MBTL1 1949/4885DYRK1A 1086/4885KEAP1 2451/4885 |
| US-20220289732-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | WDR5, WDR77, WDR1 | L3MBTL1 1713/4885DYRK1A 3640/4885KEAP1 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.